Beneficial Ownership Report · SCHEDULE 13D/A

Guardian Pharmacy Services, Inc.

GRDNNYSEEQUITYCurrent

Beneficial Ownership Report

Filed Sep 28, 2026Accepted Sep 28, 2026, 5:02 PM EDTFiling CIK 2038820Accession 0001193125-26-405492

View company →Permanent SEC source ↗

Structured filing — SCHEDULE 13D/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company: Guardian Pharmacy Services, Inc.
Company CIK: 0001802255
Street: 300 Galleria Parkway SE
Street (continued): Suite 800
City: Atlanta
State / country code: GA
Postal code: 30339

Statement details

Amendment number: 4
Security class: Class A Common Stock, par value $0.001 per share
Event date: 09/27/2026
Previously filed indication: false

Authorized notification person 1

Name: Bindley Capital Partners I LLC
Phone: (317) 704-4162
Street: (Attn: William E. Bindley)
Street (continued): 8909 Purdue Road, Suite 500
City: Indianapolis
State / country code: IN
Postal code: 46268

Reporting person 1

Name: Bindley Capital Partners I, LLC
Reporting person CIK: 0002038820
No reporting person CIK indication: N
Citizenship / organization: IN
Reporting person type: OO
Group designation: a
Source of funds code: OO
Legal proceedings indication: N
Aggregate amount owned: 16,669,666
Percent of class: 26.3
Sole voting power: 16,669,666
Shared voting power: 0
Sole dispositive power: 16,669,666
Shared dispositive power: 0
Aggregate excludes certain shares: N
Comments: The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock, par value $0.001 per share ("Class A common stock") outstanding as of September 27, 2026, of Guardian Pharmacy Services, Inc. (the "Issuer") as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 10, 2026 (the "8-K").

Reporting person 2

Name: William E. Bindley
Reporting person CIK: 0000903539
No reporting person CIK indication: N
Citizenship / organization: X1
Reporting person type: IN
Group designation: a
Source of funds code: OO
Legal proceedings indication: N
Aggregate amount owned: 16,669,666
Percent of class: 26.3
Sole voting power: 0
Shared voting power: 16,669,666
Sole dispositive power: 0
Shared dispositive power: 16,669,666
Aggregate excludes certain shares: N
Comments: William E. Bindley shares voting and investment power with Thomas J. Salentine, Jr. over an aggregate of 16,669,666 shares of Class A common stock currently owned by Bindley Capital Partners I, LLC ("Bindley Capital") by virtue of his position as member and officer of Bindley Capital Partners, LLC, the manager of Bindley Capital. The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K.

Reporting person 3

Name: Thomas J. Salentine, Jr.
Reporting person CIK: 0002037899
No reporting person CIK indication: N
Citizenship / organization: X1
Reporting person type: IN
Group designation: a
Source of funds code: OO · PF
Legal proceedings indication: N
Aggregate amount owned: 16,705,380
Percent of class: 26.4
Sole voting power: 35,714
Shared voting power: 16,669,666
Sole dispositive power: 35,714
Shared dispositive power: 16,669,666
Aggregate excludes certain shares: N
Comments: Thomas J. Salentine, Jr. directly owns 35,714 shares of Class A common stock. Mr. Salentine, Jr. also shares voting and investment power with William E. Bindley over an aggregate of 16,669,666 shares of Class A common stock currently owned by Bindley Capital by virtue of his position as member and officer of Bindley Capital Partners, LLC, the manager of Bindley Capital. The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K.

Reporting person 4

Name: Pharmacy Investors, LLC
Reporting person CIK: 0002038519
No reporting person CIK indication: N
Citizenship / organization: IN
Reporting person type: OO
Group designation: a
Source of funds code: OO
Legal proceedings indication: N
Aggregate amount owned: 3,863,806
Percent of class: 6.1
Sole voting power: 3,863,806
Shared voting power: 0
Sole dispositive power: 3,863,806
Shared dispositive power: 0
Aggregate excludes certain shares: N
Comments: The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K.

Reporting person 5

Name: John Ackerman
Reporting person CIK: 0002037898
No reporting person CIK indication: N
Citizenship / organization: X1
Reporting person type: IN
Group designation: a
Source of funds code: OO
Legal proceedings indication: N
Aggregate amount owned: 3,863,806
Percent of class: 6.1
Sole voting power: 3,863,806
Shared voting power: 0
Sole dispositive power: 3,863,806
Shared dispositive power: 0
Aggregate excludes certain shares: N
Comments: John Ackerman has voting and investment power over an aggregate of 3,863,806 shares of Class A common stock currently owned by Pharmacy Investors, LLC ("Pharmacy Investors") by virtue of his position as Manager of Pharmacy Investors. The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K.

Reporting person 6

Name: Cardinal Equity Fund, L.P.
Reporting person CIK: 0001432819
No reporting person CIK indication: N
Citizenship / organization: DE
Reporting person type: PN
Group designation: a
Source of funds code: OO
Legal proceedings indication: N
Aggregate amount owned: 1,287,237
Percent of class: 2.0
Sole voting power: 1,287,237
Shared voting power: 0
Sole dispositive power: 1,287,237
Shared dispositive power: 0
Aggregate excludes certain shares: N
Comments: Investment and voting decisions for the shares held by Cardinal Equity Fund, L.P. ("Cardinal") require unanimous consent of the investment committee of Cardinal Equity Partners, LLC, the general partner of Cardinal. The investment committee consists of John Ackerman, James L. Smeltzer, Peter J. Munson and Michael E. Smith. Therefore, no individual member of the investment committee is deemed to be the beneficial owner of the shares reported in this Schedule 13D. The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K.

Reporting person 7

Name: Fred P. Burke
Reporting person CIK: 0002037972
No reporting person CIK indication: N
Citizenship / organization: X1
Reporting person type: IN
Group designation: a
Source of funds code: OO
Legal proceedings indication: N
Aggregate amount owned: 3,438,064
Percent of class: 5.4
Sole voting power: 3,438,064
Shared voting power: 0
Sole dispositive power: 3,438,064
Shared dispositive power: 0
Aggregate excludes certain shares: N
Comments: The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K.

Reporting person 8

Name: David K. Morris
Reporting person CIK: 0002037977
No reporting person CIK indication: N
Citizenship / organization: X1
Reporting person type: IN
Group designation: a
Source of funds code: OO
Legal proceedings indication: N
Aggregate amount owned: 877,004
Percent of class: 1.4
Sole voting power: 877,004
Shared voting power: 0
Sole dispositive power: 877,004
Shared dispositive power: 0
Aggregate excludes certain shares: N
Comments: The shares reported in Rows 7, 9 and 11 in the table above exclude 641,870 shares of Class A common stock that Mr. Morris has agreed to transfer on or before November 11, 2026 pursuant a September 2025 domestic relations order, as previously disclosed. The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K.

Reporting person 9

Name: G. Kendall Forbes
Reporting person CIK: 0002038507
No reporting person CIK indication: N
Citizenship / organization: X1
Reporting person type: IN
Group designation: a
Source of funds code: OO
Legal proceedings indication: N
Aggregate amount owned: 1,651,059
Percent of class: 2.6
Sole voting power: 1,651,059
Shared voting power: 0
Sole dispositive power: 1,651,059
Shared dispositive power: 0
Aggregate excludes certain shares: N
Comments: The percentage reflected in Row 13 in the table above is calculated based on 63,320,304 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K.

Item 1

Issuer

Guardian Pharmacy Services, Inc.

Security title

Class A Common Stock, par value $0.001 per share

Principal address

Comment

EXPLANATORY NOTE: This Schedule 13D serves as Amendment No. 4 ("Amendment No. 4") to the Statement on Schedule 13D initially filed by the Reporting Persons (as defined below) on February 3, 2025, as amended by Amendment No. 1 thereto filed on May 29, 2025, Amendment No. 2 thereto filed on July 29, 2025, and Amendment No. 3 thereto filed on March 24, 2026 (and as further amended by this Amendment No. 4, the "Schedule 13D"). Except as specifically provided herein, this Amendment No. 4 does not modify any information previously reported in the Schedule 13D. Capitalized terms used but not defined in this Amendment No. 4 shall have the same meanings herein as are ascribed to such terms in the Schedule 13D. This Amendment No. 4 is being jointly filed by Bindley Capital Partners I, LLC ("Bindley Capital"), William E. Bindley, Thomas J. Salentine, Jr., Pharmacy Investors, LLC ("Pharmacy Investors"), John Ackerman, Cardinal Equity Fund, L.P. ("Cardinal"), Fred P. Burke, David K. Morris and G. Kendall Forbes (each a "Reporting Person," and collectively, the "Reporting Persons").

Item 3

Source of funds

As of the date hereof, the Reporting Persons, collectively, beneficially own 27,822,550 shares of Class A common stock.

Item 5

Number of shares

The aggregate number and percentage of shares of Class A common stock beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares of Class A common stock as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on Rows 7 through 11 and Row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference.

Transactions

Except as set forth in the Schedule 13D, no transactions in the shares of Class A common stock were effected by the Reporting Persons, or, to the knowledge of the Reporting Persons, any of the persons listed on Schedule A hereto in the 60 days preceding the date of the Schedule 13D.

Other persons with an interest

Except as described herein, to the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of Class A common stock of the Issuer beneficially owned by the Reporting Persons as described in this Item 5.

Date ownership ceased to exceed 5%

Not applicable.

Percentage of class

As of the date hereof, the Reporting Persons, collectively, beneficially own 27,822,550 shares of Class A common stock, representing approximately 43.9% of the shares of Class A common stock, calculated based on 63,320,300 shares of Class A common stock outstanding as disclosed in the 8-K. Of the 63,320,300 shares of Class A common stock currently outstanding, 13,521,396 shares of Class A common stock were issued upon the automatic conversion of an equal number of shares of the Issuer's Class B common stock, par value $0.001 per share, on September 27, 2026, pursuant to the Issuer's Amended and Restated Certificate of Incorporation.

Item 7

Filed exhibits

Exhibit 99.1 Stockholders' Agreement, dated as of September 25, 2024, by and among Guardian Pharmacy Services, Inc., Bindley Capital Partners I, LLC, Pharmacy Investors, LLC, Cardinal Equity Fund LP, Fred Burke, David Morris and Kendall Forbes (incorporated by reference to Exhibit 4.1 of the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 30, 2024). Exhibit 99.2 Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Exchange Act (incorporated by reference to the Schedule 13D filed with the Securities and Exchange Commission on February 3, 2025).

Signature 1

Reporting person: Bindley Capital Partners I, LLC
Signed: /s/ Thomas J. Salentine, Jr.
Title: Member
Date: 09/28/2026

Signature 2

Reporting person: William E. Bindley
Signed: /s/ William E. Bindley, individually
Title: William E. Bindley, individually
Date: 09/28/2026

Signature 3

Reporting person: Thomas J. Salentine, Jr.
Signed: /s/ Thomas J. Salentine, Jr., individually
Title: Thomas J. Salentine, Jr., individually
Date: 09/28/2026

Signature 4

Reporting person: Pharmacy Investors, LLC
Signed: /s/ John Ackerman
Title: Managing Member
Date: 09/28/2026

Signature 5

Reporting person: John Ackerman
Signed: /s/ John Ackerman, individually
Title: John Ackerman, individually
Date: 09/28/2026

Signature 6

Reporting person: Cardinal Equity Fund, L.P.
Signed: /s/ John Ackerman, by Cardinal Equity Partners, LLC, its General Partner
Title: Managing Member
Date: 09/28/2026

Signature 7

Reporting person: Fred P. Burke
Signed: /s/ Fred P. Burke, individually
Title: Fred P. Burke, individually
Date: 09/28/2026

Signature 8

Reporting person: David K. Morris
Signed: /s/ David K. Morris, individually
Title: David K. Morris, individually
Date: 09/28/2026

Signature 9

Reporting person: G. Kendall Forbes
Signed: /s/ G. Kendall Forbes, individually
Title: G. Kendall Forbes, individually
Date: 09/28/2026

Company context

Guardian Pharmacy Services is one of the nation’s leading long-term care pharmacy services companies. Through its locally-based business model, Guardian partners with long-term care facilities (“LTCFs”) to deliver medications and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. With a growing network of 61 licensed pharmacies, of which 54 are full-service, Guardian is dedicated to providing exceptional service to approximately 207,000 residents (as of March 31, 2026).

Current securities

GRDNNYSE · EQUITY · Current